Treatment of severe reflux esophagitis with cimetidine and metoclopramide

D. A. Lieberman, E. B. Keeffe

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


Reflux esophagitis may be unresponsive to standard medical therapy with an H2-receptor antagonist drug. Twenty-five patients with chronic reflux esophagitis, refractory to cimetidine treatment alone, were randomly assigned in a double-blind design to receive cimetidine (1200 mg/d), in combination with metoclopramide (40 mg/d) or placebo. Nine of twelve patients receiving cimetidine with metoclopramide had significant symptomatic improvement at the end of the 8-week study period, compared with 3 of 12 patients receiving cimetidine with placebo (p<0.02). Endoscopic appearance improved in 9 patients receiving metoclopramide and in 4 patients receiving placebo (p<0.05). Neither group had significant improvement in lower esophageal sphincter pressure, 24-hour esophageal pH recordings, and esophageal histologic findings. Side effects were common with cimetidine and metoclopramide but were rarely disabling. This combination is efficacious in the management of chronic reflux esophagitis but, because of frequent side effects, should be reserved for patients refractory to treatment with cimetidine alone.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalAnnals of internal medicine
Issue number1
StatePublished - 1986

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Treatment of severe reflux esophagitis with cimetidine and metoclopramide'. Together they form a unique fingerprint.

Cite this